Ionis Pharmaceuticals, Inc.
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$76.41
Price+1.36%
$1.03
1Y
Price
Market Cap
$12.627b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-47.7%
EBITDA Margin-37.6%
Net Profit Margin-331.0%
Free Cash Flow Margin-47.7%
EBITDA Margin-37.6%
Net Profit Margin-331.0%
Free Cash Flow MarginRevenue
$1.058b
+12.1%
1y CAGR+11.8%
3y CAGR+17.4%
5y CAGREarnings
-$326.583m
+14.3%
1y CAGR+2.1%
3y CAGR-7.3%
5y CAGREPS
-$2.09
+12.2%
1y CAGR+5.1%
3y CAGR-4.9%
5y CAGRBook Value
$491.414m
$3.450b
Assets$2.959b
Liabilities$2.041b
DebtDebt to Assets
59.2%
0.4x
Debt to EBITDAFree Cash Flow
-$971.257m
-203.5%
1y CAGR-75.0%
3y CAGR-59.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company